Kamu erişimi zorunlu olan makaleler - Andrew VernonDaha fazla bilgi edinin
Bir yerde sunuluyor: 21
Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible …
P Nahid, SE Dorman, N Alipanah, PM Barry, JL Brozek, A Cattamanchi, ...
Clinical infectious diseases 63 (7), e147-e195, 2016
Zorunlu olanlar: US National Institutes of Health, World Health Organization
Four-month rifapentine regimens with or without moxifloxacin for tuberculosis
SE Dorman, P Nahid, EV Kurbatova, PPJ Phillips, K Bryant, KE Dooley, ...
New England Journal of Medicine 384 (18), 1705-1718, 2021
Zorunlu olanlar: US National Institutes of Health
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis
SE Dorman, JL Johnson, S Goldberg, G Muzanye, N Padayatchi, ...
American journal of respiratory and critical care medicine 180 (3), 273-280, 2009
Zorunlu olanlar: US National Institutes of Health
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis
D Menzies, A Benedetti, A Paydar, I Martin, S Royce, M Pai, A Vernon, ...
PLoS medicine 6 (9), e1000146, 2009
Zorunlu olanlar: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé
Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis
D Menzies, A Benedetti, A Paydar, S Royce, M Pai, W Burman, A Vernon, ...
PLoS medicine 6 (9), e1000150, 2009
Zorunlu olanlar: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé
Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations
M Weiner, C Peloquin, W Burman, CC Luo, M Engle, TJ Prihoda, ...
Antimicrobial agents and chemotherapy 54 (10), 4192-4200, 2010
Zorunlu olanlar: US National Institutes of Health
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium
SE Dorman, S Goldberg, JE Stout, G Muzanyi, JL Johnson, M Weiner, ...
The Journal of infectious diseases 206 (7), 1030-1040, 2012
Zorunlu olanlar: US National Institutes of Health
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial
SE Dorman, RM Savic, S Goldberg, JE Stout, N Schluger, G Muzanyi, ...
American journal of respiratory and critical care medicine 191 (3), 333-343, 2015
Zorunlu olanlar: US National Institutes of Health, US Department of Veterans Affairs
Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the …
TR Sterling, RN Moro, AS Borisov, E Phillips, G Shepherd, NF Adkinson, ...
Clinical Infectious Diseases 61 (4), 527-535, 2015
Zorunlu olanlar: US National Institutes of Health
The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials
A Vernon, K Fielding, R Savic, L Dodd, P Nahid
PLoS medicine 16 (12), e1002884, 2019
Zorunlu olanlar: UK Medical Research Council
Exposure to latent tuberculosis treatment during pregnancy. The PREVENT TB and the iAdhere trials
RN Moro, NA Scott, A Vernon, NK Tepper, SV Goldberg, K Schwartzman, ...
Annals of the American Thoracic Society 15 (5), 570-580, 2018
Zorunlu olanlar: US National Institutes of Health
The value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse
CD Hamilton, JE Stout, PC Goodman, A Mosher, R Menzies, ...
The International Journal of Tuberculosis and Lung Disease 12 (9), 1059-1064, 2008
Zorunlu olanlar: US National Institutes of Health
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial
SE Dorman, P Nahid, EV Kurbatova, SV Goldberg, L Bozeman, ...
Contemporary clinical trials 90, 105938, 2020
Zorunlu olanlar: US National Institutes of Health
The association between symptoms and microbiologically defined response to tuberculosis treatment
CM Hales, CM Heilig, R Chaisson, CC Leung, KC Chang, SV Goldberg, ...
Annals of the American Thoracic Society 10 (1), 18-25, 2013
Zorunlu olanlar: US National Institutes of Health
Novel regimens of bedaquiline-pyrazinamide combined with moxifloxacin, rifabutin, delamanid and/or OPC-167832 in murine tuberculosis models
R Tasneen, A Garcia, PJ Converse, MD Zimmerman, V Dartois, ...
Antimicrobial agents and chemotherapy 66 (4), e02398-21, 2022
Zorunlu olanlar: US National Institutes of Health
Advances in clinical trial design: weaving tomorrow’s TB treatments
C Lienhardt, A Nunn, R Chaisson, AA Vernon, M Zignol, P Nahid, ...
PLoS medicine 17 (2), e1003059, 2020
Zorunlu olanlar: UK Medical Research Council
Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with human immunodeficiency virus (S31/A5349)
AC Pettit, PPJ Phillips, E Kurbatova, A Vernon, P Nahid, R Dawson, ...
Clinical Infectious Diseases 76 (3), e580-e589, 2023
Zorunlu olanlar: US National Institutes of Health
Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis
M Weiner, J Gelfond, TL Johnson-Pais, M Engle, JL Johnson, ...
Journal of Antimicrobial Chemotherapy 76 (3), 582-586, 2021
Zorunlu olanlar: US National Institutes of Health, US Department of Veterans Affairs
Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial
RN Moro, TR Sterling, J Saukkonen, A Vernon, CR Horsburgh, ...
The International Journal of Tuberculosis and Lung Disease 21 (3), 286-296, 2017
Zorunlu olanlar: US National Institutes of Health
Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine
NA Scott, C Sadowski, A Vernon, B Arevalo, K Beer, A Borisov, JA Cayla, ...
Contemporary clinical trials 129, 107173, 2023
Zorunlu olanlar: US National Institutes of Health
Yayıncılık ve maddi kaynak bilgileri otomatik olarak bir bilgisayar programı tarafından belirlenmektedir